Author Archives: Marta Figueiredo

Rhythm Seeks FDA Approval of Setmelanotide for POMC/LEPR Deficiency

Rhythm Pharmaceuticals is seeking approval from the U.S. Food and Drug Administration (FDA) for its lead candidate setmelanotide to treat POMC deficiency and LEPR deficiency, two rare genetic obesity disorders. Over the next two months, the FDA will determine whether Rhythm’s new drug application (NDA) is acceptable for filing…